Notizia - Recent Pharma, Healthcare and Biotech Happenings

recent-pharma-happenings-for-j-j-anokion-bms-roche

J&J ‘s COVID-19 vaccine; Roche, AC Immune’s anti-Tau Alzheimer’s drug; Silverback nets $85 M; Anokion’s deal rides out BMS-Celgene merger; Coronavirus spike protein could inspire vaccine development

J&J commences COVID-19 vaccine phase 3 Johnson & Johnson has begun a 60,000-subject phase 3 evaluation of its COVID-19 vaccine. The trial will enroll participants in the U.S. and other countries with a high incidence of COVID-19 to generate data to bolster emergency use authorization early next year. J&J submitted details of phase 3 to ClinicalTrials.gov last month. At that time, J&J targeted to commence enrolling subjects in the first week of September. Today, around two weeks after the targeted start of recruitment, J&J said it had started a phase 3 trial of Ad26 vector-based vaccine Ad26.COV2.S, now also known as JNJ-78436735. AstraZene...

Explore More...

Market & Competitive Assessment

Market Size & Forecast Assessment

Medical Devices

Market Research

Subscription

Competitive Intelligence

Business Consulting

Customized Solutions

Request for Proposal

Blog

Newsletter/Whitepaper

Infographics

Case Study

Events

Press Release

Analysis & Perspective

Notizia - Recent Pharma, Healthcare and Biotech Happenings

J&J ‘s COVID-19 vaccine; Roche, AC Immune’s anti-Tau Alzheimer’s drug; Silverback nets $85 M; Anokion’s deal rides out BMS-Celgene merger; Coronavirus spike protein could inspire vaccine development

Merck’s Remicade; Sanofi, Regeneron set Kevzara; Novartis to sever; Teva puts women’s health

AZ’s benralizumab; Sanofi, Regeneron set; Nordisk preps; European countries offer

Humira’s patent; Teva laying off; GSK aims; Thermo acquires Patheon; J& J’s Invokana

Novartis, slammed by Korean scandal; FDA tweaks; Dendreon eyes; Amgen adds

Valeant’s $50M; Sanofi vows; Top pharmas team up; PhRMA expels

Lilly moves ahead; Authorities raid; Bristol-Myers, AZ in legal; PhRMA expected to weed out

Merck’s Keytruda sales; Valeant on name change; Pfizer – BMS; Amgen puts Repatha outcomes for deal

FDA Approves; AZ nabs; Nordisk settles; Novartis pays

More Views & Analysis

Merck sells biosimilars; AbbVie’s PARP; Pharma heads; Biogen looks to M&A

Samsung biosim nod sets; Lilly’s med hits; BioMarin sees pricing; Spinraza scores; Klick creates

Drug shortage; Fujifilm invests; Cobra Biologics to pump $19M; The world’s most pricey drugs

Novartis gets CAR-T drug; Shire aims to block; Xeljanz stands; Payer snubs; Lawmakers pass a bill

Cancer, diabetes and eczema on list; AbbVie’s Humira; Teva weighs $2B; Fresenius in buyout talks

Dengvaxia study; Opdivo racks up; FDA issues plant; Teva’s Rimsa fraud; Mission bags Fox grant

Valeant’s asset-sale; Sanofi coughs up $19.8M; Sanofi’s Genzyme; India’s Alkem; GSK’s inhalers

Biogen triumphs; Lilly, Pfizer, Ipsen back; Court nixes; Mylan EpiPen recall

Subscribe to our Updates

Daily

Weekly

Monthly